Innovative Therapeutics Focus ENYO Pharma specializes in developing groundbreaking therapeutics for kidney diseases, presenting opportunities to collaborate on advanced treatment solutions or supply chain partnerships for clinical development and manufacturing.
Rising Funding Momentum With recent Series C financing of $36.6 million and strategic partnerships, ENYO Pharma is poised for further clinical expansion, making it a promising partner for medical technology providers, research tools, and specialty pharmaceutical services.
Clinical Trial Engagement Currently conducting Phase 2 trials for innovative compounds like Vonafexor, the company offers opportunities to provide clinical trial support, diagnostics, and monitoring services tailored to rare and chronic kidney disease populations.
Strategic Growth Recognition ENYO Pharma's recognition on the EIC ScalingUp List highlights its potential for accelerated growth, indicating a high-profile partner for biotech solutions, investment collaborations, and strategic alliances within the healthcare ecosystem.
Technology and Data Needs Utilizing a modern tech stack, ENYO Pharma may benefit from digital health solutions, advanced analytics, and secure cloud services, offering prospects for technology vendors to support their research and operational infrastructure.
ENYO Pharma uses 8 technology products and services including Google Hosted Libraries, jQuery CDN, Open Graph, and more. Explore ENYO Pharma's tech stack below.
| ENYO Pharma Email Formats | Percentage |
| FL@enyopharma.com | 53% |
| First.Last@enyopharma.com | 36% |
| Last@enyopharma.com | 6% |
| FirstLast@enyopharma.com | 5% |
Biotechnology ResearchAuvergne-rhône-alpes, France11-50 Employees
ENYO Pharma is a clinical-stage biopharmaceutical company developing innovative therapeutics based on fibrolytic and anti-inflammatory properties for diseases with impaired kidney function. The company is conducting Phase 2 trials with its lead compound Vonafexor in Chronic Kidney Diseases (CKD) and rare kidney disease such as Alport syndrome.
Company Overview
Funding & FinancialsENYO Pharma has raised a total of $47M of funding over 1 rounds. Their latest funding round was raised on Apr 06, 2018 in the amount of $47Mas a Series B.
ENYO Pharma's revenue is estimated to be in the range of $1M$10M
Funding & FinancialsENYO Pharma has raised a total of $47M of funding over 1 rounds. Their latest funding round was raised on Apr 06, 2018 in the amount of $47Mas a Series B.
ENYO Pharma's revenue is estimated to be in the range of $1M$10M
1-888-653-2347 
support@leadiq.com